Abilify and Hypertrichosis - a phase IV clinical study of FDA data

Summary:

Hypertrichosis is reported as a side effect among people who take Abilify (aripiprazole), especially for people who are female, 20-29 old, also take Aldactone, and have Schizophrenia.

The phase IV clinical study analyzes which people have Hypertrichosis when taking Abilify. It is created by eHealthMe based on reports of 97,308 people who have side effects when taking Abilify from the FDA, and is updated regularly.

What is Abilify?

Abilify has active ingredients of aripiprazole. It is often used in depression. eHealthMe is studying from 101,441 Abilify users. Check the latest studies of Abilify.

What is Hypertrichosis?

Hypertrichosis (hair growth on the body in an amount considered abnormal) is found to be associated with 983 drugs and 896 conditions by eHealthMe. Check the latest studies of Hypertrichosis.

On Sep, 09, 2025

97,308 people reported to have side effects when taking Abilify.
Among them, 21 people (0.02%) have Hypertrichosis.

Among these 21 people:

What is the gender of people who have Hypertrichosis when taking Abilify? *

female: 76.19 %
male: 23.81 %

What is the age of people who have Hypertrichosis when taking Abilify? *

What are other drugs people take besides Abilify? *

What are other side effects people have besides Hypertrichosis? *

Muscle Spasms (muscle contraction): 7 people, 33.33%
Insomnia (sleeplessness): 7 people, 33.33%
Psychiatric Decompensation (worsening of symptoms to the state of a serious mental disorder): 7 people, 33.33%
Headache (pain in head): 7 people, 33.33%
Drowsiness: 4 people, 19.05%
Weight Increased: 3 people, 14.29%
Paleness (unusual lightness of skin colour): 3 people, 14.29%
Memory Loss: 3 people, 14.29%
Psychotic Disorder: 3 people, 14.29%
Rashes (redness): 3 people, 14.29%

What are the existing conditions these people have? *

Schizophrenia (a mental disorder characterized by a breakdown of thought processes): 7 people, 33.33%
Psychotic Disorder: 3 people, 14.29%
Stress And Anxiety: 1 person, 4.76%
Shock (a life-threatening condition with symptoms like low blood pressure, weakness, shallow breathing, cold, clammy skin): 1 person, 4.76%
Post-Traumatic Stress Disorder: 1 person, 4.76%
Narcolepsy (brain's inability to regulate sleep-wake cycles normally): 1 person, 4.76%
Insomnia (sleeplessness): 1 person, 4.76%
Delusion (a false belief or opinion): 1 person, 4.76%

* Approximation only. Some reports may have incomplete information.

Do you take Abilify and have Hypertrichosis?

- Check whether Hypertrichosis is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Abilify:

Abilify (101,441 reports)

Hypertrichosis treatments and more:

Hypertrichosis (5,082 reports)

Browse all side effects of Abilify:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Hypertrichosis:

Hypertrichosis (983 drugs)

Browse all the conditions that are associated with Hypertrichosis:

Hypertrichosis (896 conditions)

Drugs similar to Abilify and Hypertrichosis :

Related publications that referenced our studies

Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .
Cetin, M., Celik, M., Cakici, M., Polat, M., & Suner, A, "Aripiprazole-Induced Hoarseness", Turk Psikiyatri Dergisi, 2018 Jan .
Cetin M, Celik M, Cakici M, Polat M, Suner A, "Aripiprazole induced non-cardiogenic pulmonary edema: a case report", Turk Psikiyatri Dergisi, 2014 Dec .

How the study uses the data?

The study uses data from the FDA. It is based on aripiprazole (the active ingredients of Abilify) and Abilify (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.